In today’s dynamic regulatory environment, marked by potential organizational shifts and unpredictable timelines at the FDA (including PDUFA dates, PIND meetings, and center consolidations), efficient and strategic drug development in the Value-Added Medicines/505(b)(2) (VAM) space is paramount. Companies face increasing pressure to adhere to internal timelines and manage expenses effectively.
505(b)(2) Right-First-Time Strategy for Today’s FDA is a Value-Added Medicines (VAM) webinar, sponsored by RRD Biopharma Development. The webinar dives into recent real-world experiences and provides crucial insights for navigating these challenges and avoiding common pitfalls in VAM development.
Key topics:
Understanding the current FDA landscape and potential near-term disruptions.
Addressing challenges related to unpredictable regulatory timelines (PDUFA, PINDs, etc.).
Leveraging recent experiences to anticipate and overcome obstacles in the 505(b)(2) pathway.
Implementing proven strategies to avoid costly pitfalls and maintain development momentum.
Key speakers:
James G. Schwier, Executive Consultant | Chief Operations Officer & Supply Chain Expert
Jennifer DiGiacinto, PharmD, Senior Vice President, Clinical Pharmacology & Pharmacometrics, RRD Biopharma Development
Moderated by Edward Allera, Chairperson, The 505(b)(2) Platform
Watch the recording below to gain actionable insights and strategies to confidently navigate the evolving FDA landscape and drive successful VAM drug development programs.
About The 505(b)(2) Platform:
The 505(b)(2) Platform is a non-profit 506(c) business league founded to enhance the approval and acceptance of 505(b)(2) products and advocate for manufacturers of 505(b)(2) products. The 505(b)(2) Platform is a members only network of parties interested in preserving and enhancing the 505(b)(2) regulatory pathway, works with companies from around the globe to make new, enhanced, and differentiated therapeutics a reality, and assists and advocates for product companies interested in developing 505(b)(2) products.
About RRD Biopharma Development:
RRD Biopharma Development leads companies through the process of obtaining approval for drugs, vaccines, devices, and combination products by the Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global regulatory agencies. Our teams work within a quality system designed to meet global regulatory requirements.


